investors
investors
Nasdaq: eXoZymes CEO Michael Heltzen's closing...
This Michael Heltzen's (CEO of eXoZymes) closing bell speech from February 19, 2025, when...
investors
Looking at the rest of 2025 - part 4 of a...
In this video - recorded on Dec 29, 2024 - MDB Capital Group’s Lou Basenese interviews Invizyne...
investors
Go To Market Strategy - part 3 of a fireside...
In this video - recorded on Dec 29, 2024 - MDB Capital Group’s Lou Basenese interviews Invizyne...
investors
Using AI for Enzyme Engineering - part 2 of a...
In this video - recorded on Dec 29, 2024 - MDB Capital Group’s Lou Basenese interviews Invizyne...
investors
Looking back at 2024 - part 1 of a fireside...
In this video - recorded on Dec 29, 2024 - Lou Basenese interviews Michael Heltzen about going...
investors
Invizyne IPO comments by CEO Michael Heltzen
Today's Nasdaq IPO marks new era of biomanufacturing - pioneered by Invizyne's breakthrough...
investors
Dr. Lalonde: From two years and 25 scientists...
Dr. Lalonde: From two years and 25 scientists to a few scientists for a few months "When I...
investors
Dr. Lalonde: Invizyne [...] helps the...
"Invizyne is taking what nature has done and [...] putting things in a manufacturing format so we...
investors
Commercializing Invizyne’s cell-free platform -...
Commercializing Invizyne’s cell-free platform - fireside chat withZachary Karl, PhD, Vice...
investors
Invizyne IPO - KOL Call with Dr. James J....
MDB Capital President and Chief Market Strategist Lou Basenese talks with Dr. James J. Lalonde, a...
investors
Invizyne presented by Michael Heltzen & Tyler...
In this video, CEO of Invizyne, Michael Heltzen - and VP of Research, Tyler Korman, PhD -...
investors
Invizyne presented by Chris Marlett
In this video, CEO of MDB Capital Holdings, Chris Marlett, presents Invizyne. Invizyne is a...